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AbstrAct
background: The sanitary emergency created by the cOVID-19 pandemic forced us to take exceptional measures that affect 
decision-making and administration of treatments with radiotherapy. The aim of the study was to analyze the impact of the 
cOVID-19 pandemic on patients and professionals in a radiation oncology department.
Materials and methods: We implement a plan with the objectives of maintaining radiotherapy treatment in those patients 
who need it and, at the same time, reducing the risk of spreading the virus to staff and patients. This plan included measures 
aimed at limiting the patient’s stay in hospital, selecting those patients in whom radiotherapy cannot be delayed and protect-
ing against infection through the use of physical protective measures.
results: Between March 16 and May 31, 2020, 360 patients received radiotherapy in our department. In 14 patients (4.7%) 
the start of treatment was delayed by an average of 28 days. Four patients had a positive cOVID-19 polymerase chain reaction 
(pcr) (6.6% and 1.1% of tested and all patients, respectively). among the professionals, two pcrs were positive (16.6% and 4% 
of tested and all individuals, respectively). In the serology analysis 4 out of 50 department members were IgG positive (8%).
conclusions: Despite the fact that our department is located in a region with a high incidence of cOVID-19 infection, the 
impact of the pandemic on our patients and staff has been moderate. The implementation of measures against infection and 
an adequate selection of patients for treatment allows radiation oncology departments to maintain clinical activity.
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A novel coronavirus called severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) was 
identified in December 2019 in Wuhan, China, as 
the cause of a respiratory infection called corona-
virus disease (COVID-19). The infection spread 
throughout the rest of the world and was declared 
a pandemic by the World Health Organization on 
March 11, 2020. By August 1, more than 17 million 
people had been infected and more than 680,000 
people had died from COVID-19 according to the 
World Health Organization.
The disease is characterized by fever and respi-
ratory symptoms. In most cases, patients present 
with mild illness, but up to 15% of patients require 
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hospitalization and oxygen supplementation, and 
5% progress to severe illness with respiratory failure 
and multi-organ dysfunction [1]. 
The management of cancer patients is a chal-
lenge because they have a higher risk of contract-
ing COVID-19 as well as developing a more seri-
ous disease because their immunosuppressed state 
caused by both the tumor and cancer treatments 
[2, 3]. Cancer patients undergoing chemothera-
py or surgery have a higher risk of clinically se-
vere events (odds ratio: 5.34, 95% CI: 1.80–16.18; 
p = 0.0026) after adjusting for other risk factors 
[2]. Oncologists face the dilemma of treating pa-
tients to prevent cancer progression or, conversely, 
delaying cancer treatment to prevent the spread of 
COVID-19. 
In this report we share our experience in the 
management of patients undergoing radiotherapy 
during the pandemic in a region with a high preva-
lence of COVID-19 infection. We analyze the im-
pact of the COVID-19 pandemic on the delivery of 
treatments in a radiation oncology department and 
determine the effectiveness of a contingency plan 
in reducing the risk of contagion for patients and 
healthcare personnel.
Materials and methods
The university hospital Puerta de Hierro is 
a public tertiary hospital that covers an area with 
population of 462,000. Around 1,600 new patients 
per year are treated in the department of Radiation 
Oncology, which has four linear accelerators and 
a high-rate brachytherapy unit. The department 
is comprised of 50 members: 20 doctors (12 staff 
radiation oncologists and 8 residents), 22 radio-
therapy technicians, 5 oncology nurses, 2 nursing 
assistants and 1 administrative secretary. Before the 
pandemic, approximately 30 new patients and 300 
follow-up visits per week were seen, and a mean of 
130 patients received radiotherapy in our depart-
ment daily.
Laboratory tests
The tests were performed in the Microbiology 
laboratory of the hospital. The viral RNA in the 
nasopharyngeal swab was detected by PCR (PCR, 
cobas® SARS-CoV-2, Roche). COVID-19 ELISA 
IgM+IgA and IgG (Vircell) was used for detection 
of specific antibodies in a blood sample.
contingency plan
The sanitary emergency created by the pandemic 
forced us to take exceptional measures that affect 
decision-making and administration of treatments 
with radiotherapy or chemoradiotherapy. The two 
objectives of the plan were to guarantee treatment 
with radiotherapy in those patients who need it and 
to reduce the risk of spreading the virus to health-
care personnel and patients.
To meet these objectives, measures were imple-
mented aimed at limiting the patient’s stay in hos-
pital, selecting those patients in whom radiotherapy 
cannot be delayed and protecting against infection 
through the use of physical protective measures.
Some of the measures adopted were the follow-
ing:
• follow-up visits were conducted distantly by 
phone when appropriate;
• the first visits for new patients were maintained 
except in tumors in which the delay in treatment 
was acceptable, such as benign tumors, breast 
and prostate cancer;
• various hypofractionation schemes were adopted 
whenever possible. Some of the schedules used 
in the most frequent tumors were the following:
• breast — patients > 50 years old, without boost 
and no chemotherapy: 5 weekly fractions of 2.66 
Gy/f over 5 weeks. For the rest of patients: 15 
fractions of 2.66 Gy/f with integrated boost, if 
appropriate, at 3 Gy/f,
• prostate — 20 fractions of 3 Gy/f over 4 weeks,
• lung — 20 fractions of 2.66 Gy/f over 4 weeks for 
non-small cell. For small cell limited stage, 15 
fractions of 2.66 Gy/f and prophylactic cranial 
irradiation (PCI) with 10 fractions of 2.5 Gy/fx. 
For extended stage in selected patients, 5 fx of 4 
Gy/f without PCI.
In patients with head and neck, cervical and lung 
cancers, enlargements of the overall treatment time 
were compensated by adding 0.6 Gy to the total 
dose for each day lost up to a maximum of 6 Gy;
• to assist in decision making, patients were clas-
sified according to their survival expectations 
and the potential relief of disabling symptoms 
(Tab. 1);
• patients were frequently asked about the pres-
ence of fever, cough, or dyspnea, and also about 
potential contacts with COVID-19 patients. In 
suspected cases, a PCR test, chest X-ray, and 
laboratory tests were performed to rule out CO-
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VID-19 infection. In patients with a diagnosis 
of COVID-19 pneumonia and/or positive PCR, 
treatment was interrupted until the patient had 
a clinical situation that allowed the restart of 
radiotherapy; 
• protective measures were established for all 
health personnel consisting of the use of surgical 
masks, gloves, and protective face shields. The 
accelerator table and all devices in the treatment 
room were carefully cleaned with hydroalcohol-
ic solution before each treatment. The patients 
were given a surgical mask and we tried to avoid 
crowding in the waiting room.
results
Between March 16 and May 31, 2020, 360 pa-
tients received radiotherapy in our department. 
Among them 280 patients started treatment during 
the period analyzed, which represents an average 
of 5.86 treatment initiations per day. An average 
of 86.65 daily radiotherapy sessions were admin-
istered in the four radiotherapy units and a to-
tal of 37 high-rate brachytherapy procedures were 
performed. During this period there was a 27% 
decrease in the number of patients treated with re-
spect to the same period of the previous year. This 
decrease is attributable to a lower referral of pa-
tients for postoperative radiotherapy due to a dras-
tic decrease in surgical interventions, as well as the 
delay in the start of radiotherapy in some patients. 
The start of radiotherapy was delayed in 14 pa-
tients (4.7%) according to the contingency plan or 
by patient decision. The mean delay time until the 
start of radiotherapy was 28 days (7–58).
One or more PCR tests were performed on 60 
patients (Tab. 3). The test was positive only in 4 
patients (6.6% of the patients tested and 1.1% of the 
total of 360 patients receiving radiotherapy). The 
mean time for PCR negativization was 6 days. In 2 
additional patients, the diagnosis of COVID-19 was 
established by a compatible clinical picture without 
performing PCR. Three patients presenting with 
viral pneumonia required admission and there were 
no deaths for COVID-19 in our series. In patients 
with a diagnosis of COVID-19, the mean time of 
interruption of radiotherapy was 20 days (6–45) 
and this enlargement could only be partially com-
pensated in some patients.
One or more PCRs were performed in 12 staff 
members with symptoms compatible with COV-
ID-19 infection, of which 2 were positive (16.6% of 
tested individuals and 4% of all department mem-
bers). In the seroprevalence study carried out in 
May 2020 to all members of the department, 4 out 
of 50 individuals (8%) had IgG antibodies against 
COVID-19 (Tab. 2).
As the health crisis progressed, it was necessary 
to reorganize the department’s units due to a 30% 
decrease in the workforce motivated by the recruit-
ment of doctors by the hospital administration to 
treat patients with COVID-19 and by sick leaves 
due to COVID-19 infection or quarantine.
Discussion
With 1063 confirmed cases and 130 deaths per 
100,000 populations by May 19, 2020, the autono-
mous region of Madrid is one of the European areas 
with the highest incidence of COVID-19 infection. 
The pandemic has nearly collapsed the regional 
health system due to a low availability of diagnostic 
tests and protection equipment, insufficient ICU 
beds and mechanical ventilators, and a high num-
table 1. classification of patients according to their survival expectations, risk of relapse and potential relief of disabling 
symptoms
High priority
curative treatments with survival > 50% in rapidly growing tumors in which delayed treatment can compromise 
survival 
patients with spinal cord compression in whom radiation therapy can produce neurological recovery
Medium priority
curative treatments with survival between 10–50% 
postoperative radiotherapy in patients with macroscopic residue of fast growing tumors or with 5-year recurrence 
risk > 20%
Low priority
palliative radiotherapy that produces symptomatic relief 
postoperative radiation therapy with complete resection and 5-year recurrence risk < 20%. 
radical radiotherapy in patients in whom the delay does not impact control or those in whom hormonal therapy or 
other treatment allows delay of treatment
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ber of healthcare professionals infected by COV-
ID-19. To deal with the situation created by the CO-
VID-19 pandemic we launched a contingency plan 
with the aim of maintaining radiotherapy treatment 
but reducing the spread of the virus through pro-
tective measures.
Since the beginning of the pandemic, various 
recommendations have been published regarding 
the management of radiation oncology depart-
ments [4–6]. As in our contingency plan, these 
recommendations are based on the limitation of 
the patient’s stay in the hospital; use of hypofrac-
tionation schemes; selection of high-risk patients 
in whom treatment should be performed; and in 
the adoption of protection measures against CO-
VID-19 of patients and staff.  However, the real 
impact of the COVID-19 pandemic in radiation 
oncology departments in terms of the number of 
patients and delays in radiation treatments, as well 
as the number of professionals and patients with 
COVID-19 infection has been rarely reported. Ma-
licki et al. [7] analyzed the impact of precautionary 
measures in response to COVID-19 in a large Ra-
diation Oncology center in Poland and found a re-
duction of 37% in the number of patients treated 
daily, which is similar to the 27% observed in our 
series. These authors [7] found an incidence of 2 
out of 159 tested staff members with positive PCR 
(1.2%) compared to 16.6% in our department. This 
difference is probably due to the fact that in our 
center PCR was only performed in individuals with 
symptoms or risky contact, as well as the higher 
incidence of COVID-19 infection in our region.
conclusions
Despite the fact that our department is located 
in a region with a high incidence of COVID-19 
infection, the impact of the pandemic on our pa-
tients and staff has been moderate. The imple-
mentation of measures against infection and an 
adequate selection of patients for treatment allow 
table 2. cOVID-19 pcr and cOVID-19 eLIsa IgM and IgG results in patients and healthcare professionals
Tested
individuals (%)

































IgM–, IgG+: 2/20 (10%)
IgM+, IgG+: 1/20 (5%)
IgM+, IgG–: 1/20 (5%)
IgM–, IgG–: 16/20 (80%)
IgM–, IgG+: 1/22 (4.5%)
IgM+, IgG+: 0/22 (0%)
IgM+, IgG-: 1/22 (4.5%)
IgM–, IgG–: 20/22 (90.9%)
0%
IgM–, IgG+: 2/50 (4%)
IgM+, IgG+: 2/50 (4%)
IgM+, IgG–: 2/50 (4%)
IgM–, IgG–: 46/50 (76%)
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radiation oncology departments to maintain clini-
cal activity
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